- Home
- APGE vs GNTX Comparison
APGE vs GNTX Comparison
Compare APGE & GNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APGE | GNTX |
|---|---|---|
| Founded | 2022 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 5.0B |
| IPO Year | 2023 | 1995 |
Fundamental Metrics
Financial Performance| Metric | APGE | GNTX |
|---|---|---|
| Price | $132.71 | $24.90 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 5 |
| Target Price | ★ $109.67 | $26.60 |
| AVG Volume (30 Days) | ★ 4.0M | 2.4M |
| Earning Date | 05-12-2026 | 04-24-2026 |
| Dividend Yield | N/A | ★ 2.10% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.46 |
| Revenue | N/A | ★ $2,534,268,965.00 |
| Revenue This Year | N/A | $6.89 |
| Revenue Next Year | N/A | $4.58 |
| P/E Ratio | ★ N/A | $53.80 |
| Revenue Growth | N/A | ★ 9.55 |
| 52 Week Low | $34.34 | $20.48 |
| 52 Week High | $133.16 | $29.38 |
Technical Indicators
Market Signals| Indicator | APGE | GNTX |
|---|---|---|
| Relative Strength Index (RSI) | 81.42 | 52.37 |
| Support Level | $75.41 | $22.56 |
| Resistance Level | N/A | $25.01 |
| Average True Range (ATR) | 4.21 | 0.58 |
| MACD | 5.57 | -0.09 |
| Stochastic Oscillator | 99.15 | 21.84 |
Price Performance
Historical ComparisonAbout APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
About GNTX Gentex Corporation
Gentex was founded in 1974 to produce smoke-detection equipment. The company sold its first glare-control interior mirror in 1982 and its first model using electrochromic technology in 1987. Automotive revenue is about 98% of total revenue. The company is constantly developing new applications for the technology to remain on top. Sales in 2024 totaled about $2.3 billion, with 47.7 million mirrors shipped. The unit mix breaks out as 63% interior and 37% exterior, versus 31% exterior in 2019. The company is based in Zeeland, Michigan.